Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | SLC6A7 | Q99884 | 3/20 | 0.50 |
| ▸ | FASN | P49327 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.48 |
| ▸ | OXTR | P30559 | 1/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1525473 | 0.90 | HPGD (0.53) | HPGDMAPK1KMT2ATSHRALDH1A1 | |
| SCHEMBL1927948 | 0.84 | HPGD (0.56) | HPGDMAPK1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL28020408 | 0.83 | HPGD (0.59) | HPGDMAPK1POLBKMT2ATSHR | |
| SCHEMBL3459713 | 0.79 | ALDH1A1 (0.49) | HPGDPOLBKMT2AAVPR2AVPR1A | |
| SCHEMBL4050708 | 0.76 | HPGD (0.46) | HPGDMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL3458943 | 0.76 | RECQL (0.46) | HPGDMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL6614562 | 0.75 | HPGD (1.00) | HPGDMAPK1POLBMEN1KMT2A | |
| SCHEMBL10721898 | 0.74 | MAPK1 (0.85) | HPGDMAPK1POLBMEN1KMT2A | |
| SCHEMBL3454812 | 0.74 | HPGD (0.96) | HPGDMAPK1POLBMEN1KMT2A | |
| SCHEMBL3456729 | 0.74 | HPGD (0.96) | HPGDMAPK1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144875-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2144874-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008141011-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008137609-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | HPGD 81/4885MAPK1 3571/4885POLB 1953/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | HPGD 81/4885MAPK1 3571/4885POLB 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.